Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect Study of Padsevonil Variants
NCT04283136Phase 1Withdrawn
- Sponsor
- UCB
- Start
- Feb 2020
- Primary completion
- May 2020
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of padsevonil in focal onset seizure (9 arms), sponsored by UCB. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration at 72 hours, Area Under the Plasma Concentration-Time Curve at 72 hours and 1 more. Planned start Feb 2020; status: withdrawn.
02
Drugs
padsevonil
03
Conditions
focal onset seizure
Beyond the preview
Go deeper on NCT04283136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04283136.